TY - JOUR
T1 - Assessment of Infantile Hemangiomas Using a Handheld Wireless Diffuse Optical Spectroscopic Device
AU - Fong, Christopher J.
AU - Garzon, Maria C.
AU - Hoi, Jennifer W.
AU - Kim, Hyun K.
AU - Lauren, Christine T.
AU - Morel, Kimberly
AU - Geller, Lauren
AU - Antonov, Nina
AU - Weitz, Nicole
AU - Wu, June
AU - Hielscher, Andreas H.
N1 - Funding Information:
Christopher Fong is supported by the National Science Foundation Integrative Graduate Education and Research Traineeship and a T32 grant (1T32AR059038-01A1) on Multidisciplinary Engineering Training in Musculoskeletal Research from the National Institute of Arthritis and Musculoskeletal and Skin Diseases at the National Institutes of Health.
Publisher Copyright:
© 2017 Wiley Periodicals, Inc.
PY - 2017/7/1
Y1 - 2017/7/1
N2 - Background/Objectives: Infantile hemangiomas (IHs) are vascular tumors with the potential for significant morbidity. There is a lack of validated objective tools to assess IH severity and response to treatment. Diffuse optical spectroscopy (DOS), a noninvasive, nonionizing imaging modality, can measure total hemoglobin concentration and hemoglobin oxygen saturation in tissue to assess IH vascularity and response to treatment. Our objective was to evaluate the utility of a wireless, handheld DOS system to assess IH characteristics at selected points during their clinical course. Methods: Thirteen subjects (initial age 5.8 ± 2.0 mos) with 15 IHs were enrolled. IHs were classified as proliferative, plateau phase, or involuting. Nine patients with 11 IHs were untreated; four patients with 4 IHs were treated with timolol or propranolol. Each IH was evaluated by placing the DOS system directly on the lesion as well a normal contralateral skin site. IH vascularity and oxygenation were scored using a newly defined normalized hypoxia fraction (NHF) coefficient. Measurements were recorded at various intervals from the initial visit to 1 to 2 years of age. Results: For the nine untreated IHs, the NHF was highest at 6 months of age, during proliferation. Differences in NHFs between the proliferation and the plateau (p = 0.02) and involuting (p < 0.001) stages were statistically significant. In treated patients, the NHF normalized to 60% after 2 months. One treated IH came within 5% of the NHF for normal skin after 12 months. Conclusions: DOS can be used to assess the vascularity and tissue oxygenation of IHs and monitor their progression and response to treatment.
AB - Background/Objectives: Infantile hemangiomas (IHs) are vascular tumors with the potential for significant morbidity. There is a lack of validated objective tools to assess IH severity and response to treatment. Diffuse optical spectroscopy (DOS), a noninvasive, nonionizing imaging modality, can measure total hemoglobin concentration and hemoglobin oxygen saturation in tissue to assess IH vascularity and response to treatment. Our objective was to evaluate the utility of a wireless, handheld DOS system to assess IH characteristics at selected points during their clinical course. Methods: Thirteen subjects (initial age 5.8 ± 2.0 mos) with 15 IHs were enrolled. IHs were classified as proliferative, plateau phase, or involuting. Nine patients with 11 IHs were untreated; four patients with 4 IHs were treated with timolol or propranolol. Each IH was evaluated by placing the DOS system directly on the lesion as well a normal contralateral skin site. IH vascularity and oxygenation were scored using a newly defined normalized hypoxia fraction (NHF) coefficient. Measurements were recorded at various intervals from the initial visit to 1 to 2 years of age. Results: For the nine untreated IHs, the NHF was highest at 6 months of age, during proliferation. Differences in NHFs between the proliferation and the plateau (p = 0.02) and involuting (p < 0.001) stages were statistically significant. In treated patients, the NHF normalized to 60% after 2 months. One treated IH came within 5% of the NHF for normal skin after 12 months. Conclusions: DOS can be used to assess the vascularity and tissue oxygenation of IHs and monitor their progression and response to treatment.
UR - http://www.scopus.com/inward/record.url?scp=85019855361&partnerID=8YFLogxK
U2 - 10.1111/pde.13150
DO - 10.1111/pde.13150
M3 - Article
C2 - 28548465
AN - SCOPUS:85019855361
VL - 34
SP - 386
EP - 391
JO - Pediatric Dermatology
JF - Pediatric Dermatology
SN - 0736-8046
IS - 4
ER -